Rentschler Biopharma

Rentschler Biopharma is a leading, independent, family-owned CDMO with a strong track record in biologics manufacturing, contributing to nearly 25% of FDA-approved biopharmaceuticals in 2023. It provides end-to-end services from process development to commercial manufacturing, emphasizing complex molecules and client program management. With approximately 1,400 employees and a reputation for reliability and regulatory expertise, it is a key partner for biotech and pharma companies navigating the path from concept to market.

Integrated CDMO services for complex biologics, specializing in mammalian cell culture (CHO), process development, analytical testing, and GMP manufacturing for monoclonal antibodies, recombinant proteins, biosimilars, and rare disease therapies.

Rentschler competes in a crowded global CDMO market with large players like Lonza, Samsung Biologics, and Fujifilm Diosynth, as well as many mid-sized specialists. Its differentiation lies in its deep expertise in complex molecules, family-owned long-term partnership model, and strong regulatory track record in both the US and EU.